» Articles » PMID: 17508005

CTLA-4 Blockade in Murine Bone Marrow Chimeras Induces a Host-derived Antileukemic Effect Without Graft-versus-host Disease

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2007 May 18
PMID 17508005
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

We studied the effect of CTLA-4 blockade on graft-versus-leukemia and graft-versus-host responses in a mouse model of minor histocompatibility-mismatched bone marrow transplantation. Early CTLA-4 blockade induced acute graft-versus-host disease. Delayed CTLA-4 blockade resulted in a lethal condition with lymphosplenomegaly, but with stable mixed T-cell chimerism, unchanged alloreactive T-cell frequencies and absent anti-host reactivity in vitro. In contrast, multiorgan lymphoproliferative disease with autoimmune hepatitis and circulating anti-DNA auto-antibodies were documented. Splenic lymphocytes exhibited ex vivo spontaneous proliferation and a marked proliferative response against host-type dendritic cells pulsed with syngeneic (host-type) tissue-peptides. Both phenomena were exclusively mediated by host and not donor T cells, supporting an autoimmune pathogenesis. Selectively host-derived T-cell immune reactivity was equally documented against leukemia-peptide-pulsed dendritic cells, and this was paralleled by a strong in vivo antileukemic effect in anti-CTLA-4-treated and subsequently leukemia-challenged chimeras. In conclusion, delayed CTLA-4 blockade induced a host-derived antileukemic effect, occurring in the context of an autoimmune syndrome and strictly separated from graft-versus-host disease. Both antileukemic and autoimmune responses depended on the allogeneic component, as neither effect was seen after syngeneic bone marrow transplantation. Our findings reveal the potential of using CTLA-4 blockade to establish antileukemic effects after allogeneic hematopoietic stem cell transplantation, provided autoimmunity can be controlled.

Citing Articles

A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.

Chen Y, Wang J, Zhang F, Liu P Front Pharmacol. 2023; 14:1151032.

PMID: 37153761 PMC: 10154606. DOI: 10.3389/fphar.2023.1151032.


Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.

Aureli A, Marziani B, Sconocchia T, Del Principe M, Buzzatti E, Pasqualone G Cancers (Basel). 2021; 13(24).

PMID: 34944865 PMC: 8699368. DOI: 10.3390/cancers13246246.


[Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation].

Wu H, Zhao Y, Huang H Zhonghua Xue Ye Xue Za Zhi. 2021; 42(10):869-877.

PMID: 34788930 PMC: 8607022. DOI: 10.3760/cma.j.issn.0253-2727.2021.10.014.


The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.

Kohler N, Ruess D, Kesselring R, Zeiser R Front Immunol. 2021; 12:634435.

PMID: 33746972 PMC: 7973115. DOI: 10.3389/fimmu.2021.634435.


Role of T cell immune response cDNA 7 on the pathology of acute graft-versus-host disease.

Zhu F, Xu Y, Fan X, Zhang F, Wang D, Qiao J Oncol Lett. 2020; 20(6):300.

PMID: 33101494 PMC: 7577082. DOI: 10.3892/ol.2020.12163.